VKTX | Jubak Picks

Need more GLP? Buying Viking Therapeutics on trial results

February 29, 2024 @ 7:45 pm | Breaking News, Jubak Picks Portfolio, VKTX | 0 comments

Yesterday, February 28, development-stage biotech Viking Therapeutics (VKTX) announced results from a Phase 2 trial of its GLP-1 weight-loss drug candidate that that showed the potential for the VK2735 compound to be best in class in the $36.5 billion (revenue) market...

Need more GLP? Buying Viking Therapeutics on trial results

Jim’s Daily Email Alerts: